Research on soft tissue sarcomas

Research into soft tissue sarcomas is conducted at the SIREDO Center and across several Institut Curie labs.

Focus areas include:

• Improved diagnosis and treatments for rhabdoid tumors via somatic genetics,
• Use of larotrectinib for tumors with the NTRK mutation,
• Identification of prognostic markers and molecular signatures for infantile fibrosarcomas and rhabdomyosarcomas,
• Detection of minimal circulating disease for improved sarcoma diagnosis, early detection of relapse and better analysis of chemotherapy efficacy,
• Certain very rare sarcomas.

Institut Curie’s pediatric department is LRIPH (Lieu de Recherches Impliquant la Personne Humaine) authorized by the Regional Health Agency (ARS) for early-phase clinical trials in children. When appropriate, children with soft tissue sarcomas may be offered participation in clinical trials for promising new treatments—sometimes even from the start of treatment, depending on molecular findings. In some cases, molecular abnormalities identified at diagnosis result in these new drugs being offered as early as the first line of treatment within experimental protocols.

Finally, Institut Curie plays a key role in national and international basic research programs in partnership with patient advocacy groups, with the goal of developing innovative therapies such as immunotherapy and targeted treatments. It co-founded and leads Paris Kids Cancer, an integrated pediatric oncology research center, and recently joined the EU CAN KIDS alliance, which aims for a future without pediatric cancer.

Find out more about Paris Kids Cancer